Custopharm, Inc. v. Exela Pharma Sciences, LLC

CourtDistrict Court, S.D. California
DecidedSeptember 13, 2021
Docket3:20-cv-01587
StatusUnknown

This text of Custopharm, Inc. v. Exela Pharma Sciences, LLC (Custopharm, Inc. v. Exela Pharma Sciences, LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Custopharm, Inc. v. Exela Pharma Sciences, LLC, (S.D. Cal. 2021).

Opinion

7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 CUSTOPHARM, INC., a Texas Case No.: 3:20-cv-01587-AJB-DEB 11 Corporation, 12 ORDER GRANTING DEFENDANT’S Plaintiff, MOTION TO DISMISS WITH 13 LEAVE TO AMEND 14 v. (Doc. No. 3) 15 EXELA PHARMA SCIENCES, LLC, 16 a Delaware Limited Liability Company,

17 Defendant. 18 Pending before the Court is Defendant Exela Pharma Sciences, LLC’s 19 (“Defendant”) motion to dismiss Plaintiff CustoPharm, Inc.’s (“Plaintiff”) Complaint. 20 (Doc. No. 3.) Plaintiff filed an opposition to the motion, (Doc. No. 6), and Defendant 21 replied, (Doc. No. 8). For the reasons set forth below, the Court GRANTS Defendant’s 22 motion and DISMISSES WITH LEAVE TO AMEND Plaintiff’s Complaint. 23 I. BACKGROUND 24 This action stems from an alleged breach of contract. On or about May 19, 2009, 25 Plaintiff entered into a written referral fee agreement (“Referral Agreement”) with 26 Defendant. (Doc. No. 1 ¶ 6.) Under the Referral Agreement, Plaintiff agreed to refer 27 business to Defendant “for the production of pre-launch clinical trial materials and 28 1 production of development and commercial drug products[.]” (Id.) In consideration for 2 referring new business, Defendant promised to (1) “keep any such information disclosed 3 by [Plaintiff] confidential and not disclose such information to any third party, or use such 4 information for their own benefit to start a new project” and (2) “pay [Plaintiff a] five 5 percent (5%) commission on all payments received from any referral that resulted in a drug 6 product being manufactured by [Defendant].” (Id. ¶ 8.) The commission included “any 7 payments received from the referral, including payments received from R & D work, 8 pre-launch development activities, commercial drug produce [sic] manufacturing and 9 royalties from referred business.” (Id. ¶ 9.) Commission payments were due within thirty 10 days of Defendant receiving payments from the referred business, with a one and a half 11 percent (1.5%) late fee. (Id.) 12 At the time of the Referral Agreement, “there were six (6) companies that [Plaintiff] 13 identified and [Defendant] acknowledged had been referred pursuant to the terms of the 14 Referral Agreement.” (Doc. No. 1 ¶ 10.) Since the parties executed the Referral Agreement, 15 the number of referred companies “grew to at least eleven (11) companies.” (Id.) 16 “The Referral Agreement allowed either party to terminate the Referral Agreement 17 ‘with six months written notice with all existing business surviving termination[.]’” (Id. ¶ 18 11 (quoting the Referral Agreement).) On or about April 19, 2012, Defendant provided 19 written notice to terminate the Referral Agreement and sought to agree to new terms and 20 obligations, including revising the survivability provision. (Id. ¶ 12.) However, Plaintiff 21 only accepted the notice of termination and never agreed to the new terms; Defendant’s 22 termination notice became effective on October 19, 2012. (Id. ¶ 13.) 23 The Complaint asserts claims for (1) breach of contract, (2) accounting, and (3) 24 declaratory relief. Plaintiff alleges it made “several referrals to [Defendant] that resulted in 25 the drug being manufactured by [Defendant],” (id. ¶ 17), and that Defendant owes Plaintiff 26 commissions pursuant to the Referral Agreement for “the eleven (11) companies, as well 27 as any companies referred to [Defendant] between April 19, 2012 and October 19, 2012,” 28 (id. ¶ 27). Plaintiff maintains that considering it has no way of knowing when the referred 1 companies paid Defendant, it had no way of discovering the harm it suffered “until 2 recently.” (Id. ¶ 14.) 3 II. LEGAL STANDARD 4 A Rule 12(b)(6) motion to dismiss tests the legal sufficiency of the complaint. 5 Navarro v. Block, 250 F.3d 729, 732 (9th Cir. 2001). “To survive a motion to dismiss, a 6 complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief 7 that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citation omitted). 8 Facial plausibility is satisfied “when the plaintiff pleads factual content that allows the 9 court to draw the reasonable inference that the defendant is liable for the misconduct 10 alleged.” Id. The plausibility standard is not a probability requirement, but rather, “asks for 11 more than a sheer possibility that a defendant has acted unlawfully.” Id. 12 To determine the sufficiency of the complaint, the court must assume the truth of all 13 factual allegations therein and construe them in the light most favorable to the plaintiff. 14 Cahill v. Liberty Mut. Ins. Co., 80 F.3d 336, 337–38 (9th Cir. 1996). This tenet, however, 15 does not apply to legal conclusions. Iqbal, 556 U.S. at 678. “Threadbare recitals of the 16 elements of a cause of action, supported by mere conclusory statements, do not suffice.” 17 Id.; Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555 (2007). “[W]here the well-pleaded 18 facts do not permit the court to infer more than the mere possibility of misconduct,” the 19 complaint is subject to dismissal. Iqbal, 556 U.S. at 679. 20 III. DISCUSSION 21 Defendant argues that Plaintiff’s breach of contract claim is barred by the statute of 22 limitations, and that Plaintiff has not pled facts sufficient to state a breach of contract claim. 23 (Doc. No. 3 at 9–11.)1 Defendant also contends that Plaintiff’s accounting and declaratory 24 relief claims fail because both are dependent on a breach of contract claim that is 25 time-barred and inadequately pled. (Id. at 12.) The Court discusses the viability of 26 Plaintiff’s claims in turn. 27 28 1 A. Breach of Contract 2 To begin, Defendant contends that the statute of limitations bars Plaintiff’s breach 3 of contract claim. Neither party disputes that California law applies to this issue. (Doc. 4 Nos. 3 at 9; 6 at 8.) California’s statute of limitations for a written contract is four years. 5 Cal. Code Civ. Proc. § 337. Generally, a cause of action for breach of contract “accrues at 6 the time of the breach,” and the statute begins to run “regardless of whether any damage is 7 apparent or whether the injured party is aware of their right to sue.” Perez-Encinas v. 8 AmerUs Life Ins. Co., 468 F. Supp. 2d 1127, 1134 (N.D. Cal. 2006) (citing Niles v. Louis 9 H. Rapoport & Sons, 53 Cal. App. 2d 644, 651 (1942). A court may dismiss a suit under 10 Rule 12(b)(6) based on the statute of limitations “only when ‘the running of the statute is 11 apparent on the face of the complaint.’” Von Saher v. Norton Simon Museum of Art, 592 12 F.3d 954, 969 (9th Cir. 2010) (citation omitted). Dismissal on this basis “can be granted 13 only if the assertions of the complaint, read with the required liberality, would not permit 14 the plaintiff to prove that the statute was tolled.” Jablon v. Dean Witter & Co., 614 F.2d 15 677, 682 (9th Cir. 1980). 16 Here, Plaintiff’s breach of contract claim rests on the allegation that Defendant failed 17 to pay money owed to Plaintiff under their Referral Agreement. (Doc. No. 1 at 4.) It is 18 unclear from the Complaint, however, when the alleged breach occurred. Plaintiff does 19 allege that Defendant owes Plaintiff commission payments for referrals, including “the 20 eleven (11) known companies, as well as any companies referred to [Defendant] between 21 April 19, 2012 and October 19, 2012.” (Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Anthony Jackson v. Stephen Salon
614 F.2d 15 (First Circuit, 1980)
United States v. Kenneth E. Haddock
12 F.3d 950 (Tenth Circuit, 1994)
Aryeh v. Canon Business Solutions, Inc.
292 P.3d 871 (California Supreme Court, 2013)
Niles v. Louis H. Rapoport & Sons, Inc.
128 P.2d 50 (California Court of Appeal, 1942)
April Enterprises, Inc. v. KTTV
147 Cal. App. 3d 805 (California Court of Appeal, 1983)
Gryczman v. 4550 Pico Partners, Ltd.
131 Cal. Rptr. 2d 680 (California Court of Appeal, 2003)
Perez-Encinas v. Amerus Life Insurance
468 F. Supp. 2d 1127 (N.D. California, 2006)
Fox v. Ethicon Endo-Surgery, Inc.
110 P.3d 914 (California Supreme Court, 2005)
Lopez v. Smith
203 F.3d 1122 (Ninth Circuit, 2000)
Navarro v. Block
250 F.3d 729 (Ninth Circuit, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
Custopharm, Inc. v. Exela Pharma Sciences, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/custopharm-inc-v-exela-pharma-sciences-llc-casd-2021.